MAZE
Maze Therapeutics, Inc.
NasdaqGMUSDEQUITY
DELAYED
Last price
29.84
▲ 0.91 (3.15%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
28.51
Prev close
28.93
Day high
29.84
Day low
28.98
Volume
260.77K
Market cap
—
P/E (TTM)
—
52W range
12.91 – 53.65
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+8.28%
+9.6%
1M
+6.28%
+2.6%
3M
+14.29%
+11.2%
6M
-33.45%
-44.5%
YTD
-28.96%
-41.3%
1Y
+118.32%
+98.3%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $167.50M | $0 | $0 | -100.0% |
| Operating revenue | $0 | $167.50M | $0 | $0 | -100.0% |
| Research & development | $108.45M | $83.50M | $73.94M | $88.19M | +29.9% |
| Selling, general & admin | $34.45M | $26.42M | $24.61M | $22.83M | +30.4% |
| Total operating expense | $142.90M | $109.91M | $98.55M | $111.03M | +30.0% |
| Operating income | -$142.90M | $57.59M | -$98.55M | -$111.03M | -348.1% |
| Net interest income | $11.78M | $4.65M | $1.97M | $2.03M | +153.1% |
| Pre-tax income | -$131.12M | $53.40M | -$100.42M | -$114.94M | -345.5% |
| Tax provision | $0 | $1.17M | $0 | — | -100.0% |
| Net income | -$131.12M | $52.23M | -$100.42M | -$114.94M | -351.0% |
| Net income to common | -$131.12M | $3.40M | -$100.42M | -$114.94M | -3,950.8% |
| Basic EPS | -3.05 | 0.08 | -2.87 | -3.29 | -4,021.3% |
| Diluted EPS | -3.05 | 0.08 | -2.87 | -3.29 | -4,021.3% |
| EBIT | -$142.90M | $57.59M | -$98.55M | -$111.03M | -348.1% |
| EBITDA | -$140.50M | $60.88M | -$94.46M | -$107.21M | -330.8% |
| Basic shares | 42.98M | 43.78M | 34.97M | 34.97M | -1.8% |
| Diluted shares | 42.98M | 43.78M | 35.40M | 35.40M | -1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $189.25M | $196.81M | $29.16M | $99.92M | -3.8% |
| Cash & short-term investments | $341.92M | $196.81M | $29.16M | $99.92M | +73.7% |
| Total current assets | $349.72M | $201.67M | $34.11M | $106.15M | +73.4% |
| Property, plant & equipment | $25.16M | $29.92M | $34.98M | $41.23M | -15.9% |
| Total assets | $397.13M | $240.54M | $71.50M | $149.96M | +65.1% |
| Total current liabilities | $22.56M | $20.67M | $16.32M | $20.78M | +9.1% |
| Long-term debt | — | — | $20.08M | — | — |
| Total debt | $23.31M | $26.63M | $49.62M | $32.05M | -12.5% |
| Total liabilities | $42.16M | $551.73M | $445.35M | $432.42M | -92.4% |
| Retained earnings | -$489.55M | -$358.43M | -$395.69M | -$295.27M | -36.6% |
| Shareholder equity | $354.97M | -$311.18M | -$373.85M | -$282.46M | +214.1% |
| Working capital | $327.16M | $181.00M | $17.79M | $85.37M | +80.8% |
| Net tangible assets | $354.97M | -$311.18M | -$373.85M | -$282.46M | +214.1% |
| Shares issued | 49.34M | 43.78M | 43.78M | 43.78M | +12.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$131.12M | $52.23M | -$100.42M | -$114.94M | -351.0% |
| Depreciation & amortisation | $2.40M | $3.30M | $4.09M | $3.82M | -27.1% |
| Stock-based compensation | $16.40M | $9.65M | $8.75M | $6.74M | +70.0% |
| Change in working capital | -$2.27M | -$1.52M | -$6.32M | -$3.24M | -49.2% |
| Operating cash flow | -$111.94M | $75.95M | -$86.83M | -$99.20M | -247.4% |
| Capital expenditure | -$794.00K | -$1.15M | -$441.00K | -$1.97M | +30.8% |
| Investing cash flow | -$170.96M | -$1.15M | -$441.00K | -$3.17M | -14,805.1% |
| Financing cash flow | $275.34M | $92.85M | $16.39M | $1.73M | +196.5% |
| Free cash flow | -$112.73M | $74.81M | -$87.27M | -$101.17M | -250.7% |
| End cash position | $190.34M | $197.90M | $30.25M | $101.13M | -3.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $20.00M | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $20.00M | $0 | $0 | $0 | $0 | — | — |
| Research & development | $34.15M | $27.57M | $25.19M | $28.11M | $27.58M | — | +23.9% |
| Selling, general & admin | $12.40M | $10.49M | $7.78M | $8.37M | $7.82M | — | +18.3% |
| Total operating expense | $46.55M | $38.06M | $32.97M | $36.47M | $35.40M | — | +22.3% |
| Operating income | -$26.55M | -$38.06M | -$32.97M | -$36.47M | -$35.40M | — | +30.2% |
| Net interest income | $2.35M | $3.49M | $2.88M | $2.79M | $2.62M | — | -32.8% |
| Pre-tax income | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -$32.79M | — | +30.0% |
| Tax provision | — | $0 | $0 | $0 | — | -$275.00K | — |
| Net income | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -$32.79M | — | +30.0% |
| Net income to common | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -$32.79M | — | +30.0% |
| Basic EPS | -0.45 | -0.65 | -0.66 | -0.77 | -1.15 | — | +30.8% |
| Diluted EPS | -0.45 | -0.65 | -0.66 | -0.77 | -1.15 | — | +30.8% |
| EBIT | -$23.34M | -$38.06M | -$32.97M | -$36.47M | -$32.79M | — | +38.7% |
| EBITDA | -$22.90M | -$37.56M | -$32.39M | -$35.83M | -$32.10M | — | +39.0% |
| Basic shares | 53.90M | 53.40M | 45.78M | 43.80M | 28.63M | — | +0.9% |
| Diluted shares | 53.90M | 53.40M | 45.78M | 43.80M | 28.63M | — | +0.9% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $198.77M | $189.25M | $316.77M | $264.54M | $294.37M | +5.0% |
| Cash & short-term investments | $352.38M | $341.92M | $383.94M | $264.54M | $294.37M | +3.1% |
| Accounts receivable | $20.00M | — | — | — | — | — |
| Total current assets | $379.78M | $349.72M | $391.30M | $271.15M | $299.71M | +8.6% |
| Property, plant & equipment | $23.97M | $25.16M | $26.46M | $27.71M | $28.80M | -4.7% |
| Total assets | $419.71M | $397.13M | $422.06M | $303.52M | $332.84M | +5.7% |
| Total current liabilities | $21.24M | $22.56M | $22.11M | $19.90M | $18.62M | -5.9% |
| Long-term debt | $38.83M | — | — | — | — | — |
| Total debt | $61.22M | $23.31M | $24.18M | $25.01M | $25.82M | +162.7% |
| Total liabilities | $78.01M | $42.16M | $42.62M | $41.28M | $40.77M | +85.0% |
| Retained earnings | -$513.75M | -$489.55M | -$454.98M | -$424.89M | -$391.21M | -4.9% |
| Shareholder equity | $341.70M | $354.97M | $379.44M | $262.24M | $292.07M | -3.7% |
| Working capital | $358.54M | $327.16M | $369.19M | $251.25M | $281.09M | +9.6% |
| Net tangible assets | $341.70M | $354.97M | $379.44M | $262.24M | $292.07M | -3.7% |
| Shares issued | 49.74M | 49.34M | 48.08M | 43.85M | 43.80M | +0.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -$32.79M | +30.0% |
| Depreciation & amortisation | $444.00K | $499.00K | $571.00K | $649.00K | $684.00K | -11.0% |
| Stock-based compensation | $7.11M | $6.07M | $3.86M | $3.24M | $3.23M | +17.1% |
| Change in working capital | -$23.68M | -$311.00K | $501.00K | -$1.04M | -$1.43M | -7,512.9% |
| Operating cash flow | -$39.11M | -$27.73M | -$24.64M | -$30.05M | -$29.52M | -41.0% |
| Capital expenditure | -$93.00K | -$34.00K | -$68.00K | -$393.00K | -$299.00K | -173.5% |
| Investing cash flow | $6.28M | -$103.39M | -$66.88M | -$393.00K | -$299.00K | +106.1% |
| Financing cash flow | $42.36M | $3.59M | $143.76M | $612.00K | $127.38M | +1,079.9% |
| Free cash flow | -$39.21M | -$27.76M | -$24.71M | -$30.45M | -$29.82M | -41.2% |
| End cash position | $199.85M | $190.34M | $317.86M | $265.63M | $295.46M | +5.0% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
28.22
+5.76% from price
SMA 20
28.02
+5.02% from price
SMA 50
28.13
+4.61% from price
SMA 100
27.22
+9.63% from price
SMA 200
34.40
-14.44% from price
EMA 12
28.50
+4.70% from price
EMA 26
28.28
+5.51% from price
EMA 50
28.27
+5.54% from price
RSI (14)
57.1
Neutral
MACD (12,26,9)
0.22
Hist 0.21
ATR (14)
1.47
5.00% of price
Realised vol 30D
45.2%
Annualised
Bollinger upper
29.63
20, 2σ
Bollinger lower
26.42
20, 2σ
50 / 200 cross
Death
28.13 vs 34.40
Trend bias
Below 200
-14.44%
Risk profile
Beta vs SPY
1.04
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
45.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-54.5%
Peak to trough
Max drawdown 5Y
-54.5%
Peak to trough
ATR 14
1.47
5.00% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Maze Therapeutics Announces Appointments to Its Board of Directors
GlobeNewswire · 9d ago
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
GlobeNewswire · 11d ago
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
Zacks · 32d ago
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
Motley Fool · 54d ago
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk
Simply Wall St. · 70d ago
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now
Insider Monkey · 76d ago
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Motley Fool · 78d ago
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewswire · 88d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.